Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.46 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851893 | 0.95 | MAP2K1 (0.52) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4854495 | 0.92 | MAP2K1 (0.50) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4851675 | 0.92 | MAP2K1 (0.45) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4859950 | 0.90 | MAP2K1 (0.63) | MAP2K1MAP2K2 | |
| SCHEMBL4862982 | 0.89 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL4861683 | 0.89 | MAP2K1 (0.50) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4858757 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2MEN1KMT2ATDP1 | |
| SCHEMBL4863317 | 0.87 | MAP2K1 (0.45) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4861883 | 0.87 | MAP2K1 (0.53) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4864091 | 0.87 | MAP2K1 (0.62) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885RAF1 4078/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885RAF1 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.